PPARG and cancer: Our previous work demonstrated a novel approach to overcoming cancer cell plasticity by converting invasive breast cancer cells into post-mitotic functional adipocytes through the combined use of a PPARγ agonist (Rosiglitazone) and a MEK inhibitor (Trametinib).